Lupin gets EIR from USFDA for API manufacturing facility in Visakhapatnam

19 Jun 2023 Evaluate

Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its API manufacturing facility located in Visakhapatnam (Vizag), India. The EIR was issued post the last inspection of the facility conducted from March 6, 2023 to March 10, 2023. The inspection closed with the facility receiving an inspection classification of ‘No Action Indicated’ (NAI).

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.


Lupin Share Price

2166.60 0.50 (0.02%)
21-Jan-2026 12:57 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1620.70
Dr. Reddys Lab 1163.00
Cipla 1373.30
Zydus Lifesciences 879.95
Lupin 2166.60
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×